Drugs / RNF
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00813709 Comparator | Dec 2008 → Aug 2011 | multiple sclerosis | Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RNF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00813709 ↗ |
| Route | Subcutaneous | “Single dose of RNF will be administered subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 microgram (mcg) for first 2 weeks followed by 22 mcg...” NCT00813709 ↗ |